Return-path: <terronoa@ruderfinn.com>
Envelope-to: info@riw-sv.com
Delivery-date: Wed, 01 May 2013 11:28:14 -0500
Received: from co9ehsobe004.messaging.microsoft.com ([207.46.163.27]:47650 helo=co9outboundpool.messaging.microsoft.com)
	by sprinter.websitewelcome.com with esmtps (TLSv1:AES128-SHA:128)
	(Exim 4.80)
	(envelope-from <terronoa@ruderfinn.com>)
	id 1UXZt7-0003DS-Ta
	for info@riw-sv.com; Wed, 01 May 2013 11:28:14 -0500
Received: from mail176-co9-R.bigfish.com (10.236.132.246) by
 CO9EHSOBE040.bigfish.com (10.236.130.103) with Microsoft SMTP Server id
 14.1.225.23; Wed, 1 May 2013 16:28:12 +0000
Received: from mail176-co9 (localhost [127.0.0.1])	by
 mail176-co9-R.bigfish.com (Postfix) with ESMTP id 81FC87002A9	for
 <info@riw-sv.com>; Wed,  1 May 2013 16:28:12 +0000 (UTC)
X-Forefront-Antispam-Report: CIP:157.56.236.213;KIP:(null);UIP:(null);IPV:NLI;H:BY2PRD0711HT004.namprd07.prod.outlook.com;RD:none;EFVD:NLI
X-SpamScore: -1
X-BigFish: PS-1(zzc85fh1415I2130Izz1f42h1fc6h1ee6h1de0h1fdah1202h1e76h1d1ah1d2ahzz17326ah18c673h8275bh8275dhz32i2a8h668h839hd25hf0ah1288h12a5h12bdh137ah1441h1504h1537h153bh15d0h162dh1631h1758h18e1h1946h19b5h19ceh1ad9h1b0ah1bceh1d07h1d0ch1d2eh1155h)
Received: from mail176-co9 (localhost.localdomain [127.0.0.1]) by mail176-co9
 (MessageSwitch) id 136742569162030_12183; Wed,  1 May 2013 16:28:11 +0000
 (UTC)
Received: from CO9EHSMHS024.bigfish.com (unknown [10.236.132.249])	by
 mail176-co9.bigfish.com (Postfix) with ESMTP id 0CD92A80048	for
 <info@riw-sv.com>; Wed,  1 May 2013 16:28:11 +0000 (UTC)
Received: from BY2PRD0711HT004.namprd07.prod.outlook.com (157.56.236.213) by
 CO9EHSMHS024.bigfish.com (10.236.130.34) with Microsoft SMTP Server (TLS) id
 14.1.225.23; Wed, 1 May 2013 16:28:10 +0000
Received: from BY2PRD0711MB439.namprd07.prod.outlook.com ([169.254.2.143]) by
 BY2PRD0711HT004.namprd07.prod.outlook.com ([10.255.88.167]) with mapi id
 14.16.0305.001; Wed, 1 May 2013 16:28:09 +0000
From: Alexander Terrono <terronoa@ruderfinn.com>
To: "info@riw-sv.com" <info@riw-sv.com>
Subject: Russian Innovation Week - Speaker suggestion
Thread-Topic: Russian Innovation Week - Speaker suggestion
Thread-Index: Ac5GiGn2N9c7wQkXQOiSii+b2P1jGg==
Date: Wed, 1 May 2013 16:28:09 +0000
Message-ID: <8FBC3DEC2AD7B848B340EAE3789D8E97F14790@BY2PRD0711MB439.namprd07.prod.outlook.com>
Accept-Language: en-US
Content-Language: en-US
X-MS-Has-Attach:
X-MS-TNEF-Correlator:
x-originating-ip: [209.148.56.2]
Content-Type: multipart/alternative;
	boundary="_000_8FBC3DEC2AD7B848B340EAE3789D8E97F14790BY2PRD0711MB439na_"
MIME-Version: 1.0
X-OriginatorOrg: ruderfinn.com

--_000_8FBC3DEC2AD7B848B340EAE3789D8E97F14790BY2PRD0711MB439na_
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

Hi,

I was looking into this year's Russian Innovation Week and was wondering if=
 you are still looking for speakers for your Boston conference. If you are,=
 you might be interested in Noubar Afeyan, CEO and co-founder of Flagship V=
entures, a Cambridge, MA-based venture capital firm with over a decade of e=
xperience in investing in and inventing groundbreaking companies in therape=
utics, heath technologies and sustainability. Afeyan is a member of the Boa=
rd of Trustees of the newly founded Skoltech, a Russia-based private gradua=
te research university formed in collaboration with MIT and also serves on =
the international advisory board of the Skolkovo Moscow School of Managemen=
t.

Through its venture creation arm VentureLabs, Flagship has founded the foll=
owing innovative companies among over 20 others:

*         Moderna, which is pioneering an entirely new treatment approach t=
o fighting disease through messenger RNA Therapeutics and which recently an=
nounced an unprecedented deal with AstraZeneca

*         Joule Unlimited, which is developing and commercializing liquid f=
uels derived from sunlight and CO2

*         Pronutria, which is developing a revolutionary platform for produ=
cing pure protein nutrients from sunlight

Please let me know if this is of interest. I look forward to hearing from y=
ou!
Best,
Alex

About Flagship Ventures: With over a decade of investing in and inventing g=
roundbreaking companies, Flagship Ventures operates through two synergistic=
 units: VentureLabs which invents and launches transformative companies, an=
d Venture Capital, which finances and realizes innovative, early-stage comp=
anies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ven=
tures manages over $900 million in capital. The Flagship team innovates and=
 invests in three principal business sectors: therapeutics, health technolo=
gies and sustainability/clean technology. Past successful Flagship portfoli=
o ventures include: Adnexus (acquired by Bristol-Myers Squibb), Accuri Cyto=
meters (acquired by Becton, Dickinson), Color Kinetics (acquired by Philips=
), and AVEO (NASDAQ: AVEO).

About Dr. Noubar Afeyan: Noubar is founder, Managing Partner and CEO of Fla=
gship Ventures, a leading early stage venture capital firm. During his 25-y=
ear career as inventor, entrepreneur, CEO and venture capitalist, he has co=
-founded and helped build 25 successful life science and technology startup=
s. He is a Senior Lecturer at MIT's Sloan School of Management where he has=
 taught courses on technology entrepreneurship, innovation, and leadership.=
 Noubar has authored numerous scientific publications and patents since ear=
ning his Ph.D. in Biochemical Engineering from MIT in 1987.


Alex Terrono  | Ruder Finn, Inc.
301 East 57th Street, 3rd Floor | New York, NY 10022
P: 212.593.5821 |  E: terronoa@ruderfinn.com<mailto:terronoa@ruderfinn.com>


--_000_8FBC3DEC2AD7B848B340EAE3789D8E97F14790BY2PRD0711MB439na_
Content-Type: text/html; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-micr=
osoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" =
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" xmlns=3D"http:=
//www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Dus-ascii"=
>
<meta name=3D"Generator" content=3D"Microsoft Word 14 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-priority:99;
	color:purple;
	text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
span.EmailStyle17
	{mso-style-type:personal-compose;
	font-family:"Calibri","sans-serif";
	color:windowtext;}
.MsoChpDefault
	{mso-style-type:export-only;
	font-family:"Calibri","sans-serif";}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
/* List Definitions */
@list l0
	{mso-list-id:728921914;
	mso-list-type:hybrid;
	mso-list-template-ids:-1680335174 67698689 67698691 67698693 67698689 6769=
8691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang=3D"EN-US" link=3D"blue" vlink=3D"purple">
<div class=3D"WordSection1">
<p class=3D"MsoNormal">Hi,<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal">I was looking into this year&#8217;s Russian Innovat=
ion Week and was wondering if you are still looking for speakers for your B=
oston conference. If you are, you might be interested in Noubar Afeyan, CEO=
 and co-founder of Flagship Ventures, a
 Cambridge, MA-based venture capital firm with over a decade of experience =
in investing in and inventing groundbreaking companies in therapeutics, hea=
th technologies and sustainability. Afeyan is a member of the Board of Trus=
tees of the newly founded Skoltech,
 a Russia-based private graduate research university formed in collaboratio=
n with MIT and also serves on the international advisory board of the Skolk=
ovo Moscow School of Management.<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal">Through its venture creation arm VentureLabs, Flagsh=
ip has founded the following innovative companies among over 20 others:<o:p=
></o:p></p>
<p class=3D"MsoListParagraph" style=3D"text-indent:-.25in;mso-list:l0 level=
1 lfo1"><![if !supportLists]><span style=3D"font-family:Symbol"><span style=
=3D"mso-list:Ignore">&middot;<span style=3D"font:7.0pt &quot;Times New Roma=
n&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Moderna, which is pioneering an entirely new=
 treatment approach to fighting disease through messenger RNA Therapeutics =
and which recently announced an unprecedented deal with AstraZeneca<o:p></o=
:p></p>
<p class=3D"MsoListParagraph" style=3D"text-indent:-.25in;mso-list:l0 level=
1 lfo1"><![if !supportLists]><span style=3D"font-family:Symbol"><span style=
=3D"mso-list:Ignore">&middot;<span style=3D"font:7.0pt &quot;Times New Roma=
n&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Joule Unlimited, which is developing and com=
mercializing liquid fuels derived from sunlight and CO2<o:p></o:p></p>
<p class=3D"MsoListParagraph" style=3D"text-indent:-.25in;mso-list:l0 level=
1 lfo1"><![if !supportLists]><span style=3D"font-family:Symbol"><span style=
=3D"mso-list:Ignore">&middot;<span style=3D"font:7.0pt &quot;Times New Roma=
n&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Pronutria, which is developing a revolutiona=
ry platform for producing pure protein nutrients from sunlight<o:p></o:p></=
p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal">Please let me know if this is of interest. I look fo=
rward to hearing from you!<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p></o:p></p>
<p class=3D"MsoNormal">Best,<o:p></o:p></p>
<p class=3D"MsoNormal">Alex<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal"><b>About Flagship Ventures</b>: With over a decade o=
f investing in and inventing groundbreaking companies, Flagship Ventures op=
erates through two synergistic units: VentureLabs which invents and launche=
s transformative companies, and Venture
 Capital, which finances and realizes innovative, early-stage companies. Fo=
unded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures man=
ages over $900 million in capital. The Flagship team innovates and invests =
in three principal business sectors:
 therapeutics, health technologies and sustainability/clean technology. Pas=
t successful Flagship portfolio ventures include: Adnexus (acquired by Bris=
tol-Myers Squibb), Accuri Cytometers (acquired by Becton, Dickinson), Color=
 Kinetics (acquired by Philips),
 and AVEO (NASDAQ: AVEO).<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal"><b>About Dr. Noubar Afeyan</b>: Noubar is founder, M=
anaging Partner and CEO of Flagship Ventures, a leading early stage venture=
 capital firm. During his 25-year career as inventor, entrepreneur, CEO and=
 venture capitalist, he has co-founded
 and helped build 25 successful life science and technology startups. He is=
 a Senior Lecturer at MIT&#8217;s Sloan School of Management where he has t=
aught courses on technology entrepreneurship, innovation, and leadership. N=
oubar has authored numerous scientific
 publications and patents since earning his Ph.D. in Biochemical Engineerin=
g from MIT in 1987.<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal"><b><span style=3D"font-size:10.0pt;font-family:&quot=
;Arial&quot;,&quot;sans-serif&quot;;color:#38761D;background:white"><br>
Alex Terrono</span></b><b><span style=3D"font-size:10.0pt;font-family:&quot=
;Arial&quot;,&quot;sans-serif&quot;;color:#222222;background:white">&nbsp;<=
/span></b><b><span style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;,=
&quot;sans-serif&quot;;color:#FFD966;background:white">&nbsp;|&nbsp;</span>=
</b><b><span style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;,&quot;=
sans-serif&quot;;color:#38761D;background:white">Ruder
 Finn, Inc.</span></b><b><span style=3D"font-size:10.0pt;font-family:&quot;=
Arial&quot;,&quot;sans-serif&quot;;color:#222222"><br>
</span></b><b><span style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;=
,&quot;sans-serif&quot;;color:#38761D;background:white">301 East 57th Stree=
t, 3rd Floor</span></b><b><span style=3D"font-size:10.0pt;font-family:&quot=
;Arial&quot;,&quot;sans-serif&quot;;color:#222222;background:white">&nbsp;<=
/span></b><b><span style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;,=
&quot;sans-serif&quot;;color:#FFE599;background:white">|</span></b><b><span=
 style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&q=
uot;;color:#222222;background:white">&nbsp;</span></b><b><span style=3D"fon=
t-size:10.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;color:#3=
8761D;background:white">New
 York, NY 10022</span></b><b><span style=3D"font-size:10.0pt;font-family:&q=
uot;Arial&quot;,&quot;sans-serif&quot;;color:#222222"><br>
</span></b><b><span style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;=
,&quot;sans-serif&quot;;color:#38761D;background:white">P: 212.593.5821</sp=
an></b><b><span style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;,&qu=
ot;sans-serif&quot;;color:#222222;background:white">&nbsp;</span></b><b><sp=
an style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif=
&quot;;color:#FFE599;background:white">|&nbsp;</span></b><b><span style=3D"=
font-size:10.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;color=
:#222222;background:white">&nbsp;</span></b><b><span style=3D"font-size:10.=
0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;color:#38761D;back=
ground:white">E:&nbsp;<a href=3D"mailto:terronoa@ruderfinn.com" target=3D"_=
blank"><span style=3D"color:blue">terronoa@ruderfinn.com</span></a></span><=
/b><o:p></o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
</div>
</body>
</html>

--_000_8FBC3DEC2AD7B848B340EAE3789D8E97F14790BY2PRD0711MB439na_--
